The International AIDS Vaccine Initiative (IAVI) is collaborating with NineSigma, one of the world’s topmost innovation service providers, to identify new approaches and technologies that may lead to a successful vaccine against HIV, according to an IAVI statement. NineSigma is providing its expertise to IAVI after helping accelerate innovation for global multinational corporations such as Kraft, Philips and L’Oreal. The consultation has already identified two scientists who will receive a total of $875,000 to generate stable protein complexes that can be used in AIDS vaccines.

To read the IAVI statement, click here.